Published in Immunochemistry on August 01, 1973
Effect of protein A on staphylococcal opsonization. Infect Immun (1977) 2.79
Opsonic requirements for staphylococcal phagocytosis. Heterogeneity among strains. Immunology (1977) 2.73
Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera. J Exp Med (1974) 2.47
Activation of complement by cell surface components of Staphylococcus aureus. Infect Immun (1978) 2.03
Staphylococcus aureus protein A recognizes platelet gC1qR/p33: a novel mechanism for staphylococcal interactions with platelets. Infect Immun (2000) 1.56
Classical and alternative complement pathway activation by pneumococci. Infect Immun (1977) 1.54
The role of Staphylococcus aureus cell-wall peptidoglycan, teichoic acid and protein A in the processes of complement activation and opsonization. Immunology (1979) 1.26
Chemotaxigenesis by cell surface components of Staphylococcus aureus. Infect Immun (1979) 1.17
Evidence for two immune inhibitors from Bacillus thuringiensis interfering with the humoral defense system of saturniid pupae. Infect Immun (1976) 1.12
Protein A effect on alternative pathway complement activation and opsonization of Staphylococcus aureus. Infect Immun (1981) 0.93
Antibody responses to protein A in patients with Staphylococcus aureus bacteremia and endocarditis. J Clin Microbiol (1990) 0.86
Lung clearance of Staphylococcus aureus strains with differing protein A content: protein A effect on in vivo clearance. Infect Immun (1978) 0.86
Opsonins in human serum for the phagocytosis of complexes between IgG and protein A of Staphylococcus aureus. Immunology (1978) 0.79
Activation of the alternate complement pathway in Staph. aureus infective endocarditis and its relationship to thrombocytopenia, coagulation abnormalities, and acute glomerulonephritis. Clin Exp Immunol (1978) 0.79
The interaction of protein A and Fc fragment of rabbit immunoglobulin G as probed by complement-fixation and nuclear-magnetic-resonance studies. Biochem J (1977) 0.79
IgG immunoadsorption in experimental allergic neuritis: effect on antibody levels and clinical course. J Neurol Neurosurg Psychiatry (1989) 0.78
Complement activation in Staphylococcus aureus bacteraemia. Clin Exp Immunol (1980) 0.75
Effect of staphylococcal protein A on complement-potentiated neutralization of herpes simplex virus and immune lysis of virus-infected cells. Infect Immun (1975) 0.75
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
"Protein A" from S. aureus. I. Pseudo-immune reaction with human gamma-globulin. J Immunol (1966) 9.65
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med (1977) 7.89
Human monocytes: distinct receptor sites for the third component of complement and for immunoglobulin G. Science (1968) 7.70
Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med (1969) 7.43
The C3-activator system: an alternate pathway of complement activation. J Exp Med (1971) 7.07
C3 proactivator convertase and its mode of action. J Exp Med (1972) 6.94
Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement. J Exp Med (1967) 6.72
Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol (1970) 6.58
Complement. Annu Rev Biochem (1975) 6.00
The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement. J Exp Med (1968) 5.78
The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. J Immunol (1968) 5.40
Enharncement of the hemolytic activity of the second component of human complement by oxidation. J Exp Med (1967) 5.36
Chemistry and reaction mechanisms of complement. Adv Immunol (1968) 5.02
Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci U S A (1978) 4.94
Protein A from Staphylococcus aureus. Its isolation by affinity chromatography and its use as an immunosorbent for isolation of immunoglobulins. FEBS Lett (1972) 3.91
The reaction mechanism of human C5 in immune hemolysis. J Exp Med (1970) 3.83
Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol (1985) 3.76
The second component of human complement: its isolation, fragmentation by C'1 esterase, and incorporation into C'3 convertase. J Exp Med (1968) 3.71
Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest (1970) 3.55
Complement. Annu Rev Biochem (1969) 3.51
Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (1983) 3.47
Anaphylatoxins: C3a and C5a. Adv Immunol (1978) 3.44
Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology (1993) 3.42
Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol (1980) 3.41
Molecular analysis of the membrane attack mechanism of complement. J Exp Med (1972) 3.35
Immune adherence by the fourth component of complement. Science (1969) 3.34
Deficiency of the fifth component of complement in mice with an inherited complement defect. J Exp Med (1967) 3.28
Isolation of the anticomplementary protein from cobra venom and its mode of action on C3. J Immunol (1971) 3.25
C1q deviation test for the detection of immune complexes, aggregates of IgG, and bacterial products in human serum. J Exp Med (1975) 3.21
Lysis of erythrocytes by complement in the absence of antibody. J Exp Med (1970) 3.19
Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. J Exp Med (1975) 3.12
Region X, the cell-wall-attachment part of staphylococcal protein A. Eur J Biochem (1984) 3.00
Hemolytic activity of lipoprotein-depleted serum and the effect of certain anions on complement. J Immunol (1966) 2.98
The ninth component of human complement: isolation, description and mode of action. Immunology (1969) 2.96
The reaction of monomeric and aggregated immunoglobulins with C1. Immunochemistry (1971) 2.96
Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med (1980) 2.94
Fourth component of human complement: description of a three polypeptide chain structure. J Exp Med (1974) 2.93
Studies on the mode of action of the fifth, sixth and seventh component of human complement in immune haemolysis. Immunology (1967) 2.93
Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system. N Engl J Med (1972) 2.91
Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med (1981) 2.88
Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1992) 2.84
The role of properdin in the alternate pathway of complement activation. J Exp Med (1974) 2.77
Purification and radiolabeling of human C1q. J Immunol (1981) 2.75
Deficiency of the sixth component of complement in rabbits with an inherited complement defect. J Exp Med (1966) 2.73
Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med (1976) 2.66
The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N Engl J Med (1973) 2.64
Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology (1975) 2.62
The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol (1979) 2.58
The membrane attack complex of complement. Annu Rev Immunol (1986) 2.57
Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A (1978) 2.57
Protein A isolated from Staphylococcus aureus after digestion with lysostaphin. Eur J Biochem (1972) 2.53
Formation of C3a and C5a anaphylatoxins in whole human serum after inhibition of the anaphylatoxin inactivator. J Exp Med (1973) 2.50
The membrane attack mechanism of complement. Verification of a stable C5-9 complex in free solution. J Exp Med (1973) 2.44
A comparison of methods for the molecular quantitation of the fourth component of human complement. Immunochemistry (1968) 2.44
Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci U S A (1986) 2.39
Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. J Exp Med (1979) 2.39
The classical complement pathway: activation and regulation of the first complement component. Adv Immunol (1985) 2.38
Formation of transmembrane tubules by spontaneous polymerization of the hydrophilic complement protein C9. Nature (1982) 2.35
Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med (1976) 2.34
Localization of protein A in the bacteria. Eur J Biochem (1972) 2.33
Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33
Protein A mutants of Staphylococcus aureus. J Bacteriol (1971) 2.32
Protein A from Staphylococcus aureus. IX. Complement-fixing activity of protein A-IgG complexes. J Immunol (1969) 2.28
The eighth component of human complement (C8): isolation, characterization, and hemolytic efficiency. J Exp Med (1969) 2.25
"Protein A" from Staphylococcus aureus. 3. Reaction with rabbit gamma-globulin. J Immunol (1967) 2.22
The second component of human complement (C2): quantitative molecular analysis of its reactions in immune hemolysis. Immunochemistry (1970) 2.18
Cytotoxic effects of leukocyres triggered by complement bound to target cells. Science (1969) 2.15
Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function. J Exp Med (1976) 2.13
Complement: substitution of the terminal component in immune hemolysis by 1,10-phenanthroline. Science (1967) 2.11
Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process. Virology (1984) 2.11
A molecular concept of the properdin pathway. Proc Natl Acad Sci U S A (1976) 2.09
The ninth component of human complement: purification and physicochemical characterization. J Immunol (1980) 2.09
Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin. J Clin Invest (1975) 2.07
C1q protein of human complement. Biochemistry (1972) 2.06
Immunologic injury of cultured cells infected with measles virus. I. role of IfG antibody and the alternative complement pathway. J Exp Med (1975) 2.06
Blood coagulation initiation by a complement-mediated pathway. J Exp Med (1971) 2.04
Purification of the sixth and seventh component of human complement without loss of hemolytic activity. J Immunol (1976) 2.02
The alternative pathway of complement. Springer Semin Immunopathol (1984) 2.01
Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity. J Exp Med (1981) 1.99
A blood coagulation abnormality in rabbits deficient in the sixth component of complement (C6) and its correction by purified C6. J Exp Med (1971) 1.97
Complement associated peptidase activity of guinea pig serum. I. Role of complement components. J Immunol (1967) 1.97
Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell (1989) 1.93
Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly. J Exp Med (1982) 1.92
Human serum lyses RNA tumour viruses. Nature (1975) 1.92
The membrane attack mechanism of complement: the three polypeptide chain structure of the eigth component (C8). J Exp Med (1976) 1.90